SCHEMBL2190712

SCHEMBL2190712

Cc1cc(C(=NO)Nc2ccc(F)c(Cl)c2)no1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.62
SMN1; SMN2 Q16637 8/20 0.53
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
HTT P42858 3/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45
TSHR P16473 1/20 0.45
GAA P10253 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190710 1.00 L3MBTL1 (0.62) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL14218379 0.86 L3MBTL1 (0.58) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2190877 0.85 SMN1; SMN2 (0.75) L3MBTL1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL2190879 0.85 SMN1; SMN2 (0.75) L3MBTL1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL15867714 0.84 SMN1; SMN2 (0.74) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL14272789 0.83 L3MBTL1 (0.63) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2183725 0.81 MEN1 (0.71) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2183730 0.81 MEN1 (0.71) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2192866 0.81 KMT2A (0.46) L3MBTL1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL2192869 0.81 KMT2A (0.46) L3MBTL1SMN1; SMN2MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064207-B1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORP (US) 2013-11-06 EP claimed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US claimed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US claimed
EP-2064207-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation (US) 2009-06-03 EP claimed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US claimed
WO-2008036642-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO claimed
EP-2064207-B1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORP (US) 2013-11-06 EP disclosed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US disclosed
US-8377976-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-02-19 US disclosed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US disclosed
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION, A DELAWARE CORPORATION 2011-07-14 US disclosed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US disclosed
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172279-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT L3MBTL1 4812/4885SMN1; SMN2 3241/4885MEN1 2391/4885
US-20080125470-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT L3MBTL1 4812/4885SMN1; SMN2 3241/4885MEN1 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.